Astria Therapeutics (NASDAQ:ATXS) Shares Up 5.5% – Here’s What Happened

Astria Therapeutics, Inc. (NASDAQ:ATXS) traded up 5.5% during trading on Wednesday . The stock traded as high as $10.73 and last traded at $10.72. 431,898 shares traded hands during trading, a decline of 27% from the average session volume of 594,279 shares. The stock had previously closed at $10.16.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on ATXS shares. Evercore ISI raised shares of Astria Therapeutics to a “strong-buy” rating in a research note on Wednesday, August 14th. HC Wainwright reissued a “buy” rating and issued a $16.00 price objective on shares of Astria Therapeutics in a research note on Tuesday. Wedbush reaffirmed an “outperform” rating and set a $22.00 target price on shares of Astria Therapeutics in a research note on Tuesday, August 13th. Finally, Oppenheimer raised their price target on Astria Therapeutics from $26.00 to $28.00 and gave the stock an “outperform” rating in a research note on Thursday, November 14th. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $25.60.

Astria Therapeutics Stock Performance

The firm has a market capitalization of $585.18 million, a P/E ratio of -4.96 and a beta of 0.67. The stock’s 50 day simple moving average is $10.92 and its 200 day simple moving average is $10.68.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ATXS. FMR LLC raised its holdings in shares of Astria Therapeutics by 29.2% in the 3rd quarter. FMR LLC now owns 7,822,275 shares of the biotechnology company’s stock valued at $86,123,000 after purchasing an additional 1,767,714 shares in the last quarter. Vestal Point Capital LP lifted its holdings in Astria Therapeutics by 23.1% during the third quarter. Vestal Point Capital LP now owns 4,000,000 shares of the biotechnology company’s stock worth $44,040,000 after buying an additional 750,000 shares during the period. Sofinnova Investments Inc. bought a new stake in Astria Therapeutics during the 2nd quarter valued at $552,000. ClariVest Asset Management LLC purchased a new position in shares of Astria Therapeutics in the 2nd quarter valued at $731,000. Finally, Intech Investment Management LLC bought a new position in shares of Astria Therapeutics in the 3rd quarter worth $228,000. 98.98% of the stock is currently owned by institutional investors.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.